J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 18.6 CNY 1.25% Market Closed
Market Cap: ¥14.9B

Jafron Biomedical Co Ltd
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Jafron Biomedical Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
EPS (Diluted)
¥0
CAGR 3-Years
-26%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
EPS (Diluted)
¥5
CAGR 3-Years
32%
CAGR 5-Years
49%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
EPS (Diluted)
¥1
CAGR 3-Years
11%
CAGR 5-Years
2%
CAGR 10-Years
15%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
EPS (Diluted)
¥6
CAGR 3-Years
-5%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Andon Health Co Ltd
SZSE:002432
EPS (Diluted)
¥4
CAGR 3-Years
-50%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
EPS (Diluted)
¥1
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
14.9B CNY
Industry
Health Care

In the heart of China's bustling Guangdong province, Jafron Biomedical Co., Ltd. has carved a distinguished niche in the world of biomedicine since its inception. This innovative company, recognized as a leader in the hemoperfusion field, has built its reputation on a foundation of pioneering blood purification technologies. By developing and manufacturing an array of hemoperfusion devices, Jafron offers critical solutions that aid in the removal of toxins from the bloodstream, thus improving outcomes for patients suffering from various systemic toxic reactions and kidney-related disorders. Their state-of-the-art hemoperfusion cartridges, meticulously designed for efficiency, are instrumental in managing and treating conditions such as chronic kidney disease and liver dysfunction. This relentless pursuit of quality is bolstered by a dedicated research division that harmonizes clinical insights with scientific innovation, ensuring Jafron stays at the forefront of clinical demand. Jafron Biomedical thrives on a robust business model that fuses direct sales with an expansive network of partnerships. This dual approach not only amplifies their market reach but also enables the company to establish solid footholds in key domestic and international markets. By collaborating with healthcare institutions and medical device distributors, Jafron ensures its products deliver critical health solutions to a broad clientele. The revenue streams are mainly anchored in the sales of its hemoperfusion products and through strategic expansions in emerging markets. As global health standards evolve and the demand for advanced medical solutions expands, Jafron is positioned to sustain its growth momentum by continually innovating in response to the global demand for efficient blood purification therapies. Through these methods, Jafron not only augments its economic footprint but also underscores its commitment to enhancing global healthcare standards.

Intrinsic Value
15.8 CNY
Overvaluation 15%
Intrinsic Value
Price ¥18.6
J

See Also

What is Jafron Biomedical Co Ltd's EPS (Diluted)?
EPS (Diluted)
0.6 CNY

Based on the financial report for Sep 30, 2025, Jafron Biomedical Co Ltd's EPS (Diluted) amounts to 0.6 CNY.

What is Jafron Biomedical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-9%

Over the last year, the EPS (Diluted) growth was -38%. The average annual EPS (Diluted) growth rates for Jafron Biomedical Co Ltd have been -26% over the past three years , -9% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett